• a Product Development Partnership (PDP) with a proven track record and business model that delivers results;
  • efficient and effective financial management and oversight;
  • impact on innovating and diversifying the TB vaccine pipeline, maintaining European and global excellence in the discovery and development of new TB vaccines and biomarkers;
  • potential social and economic return on investment and to make a difference in global health and poverty related diseases.